AXIM BiotechnologiesAXIM -6.17% Debt-to-EBITDA is 3.86 as of Jun. 2025. Among 291 Biotechnology companies, AXIM Biotechnologies ranks worse than 94.16% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for AXIM Biotechnologies's Debt-to-EBITDA or its related term are showing as below:
AXIM's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.16 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
AXIM Biotechnologies Debt-to-EBITDA Related Terms
AXIM Biotechnologies Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for AXIM Biotechnologies's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AXIM vs ZVSA, HEPA, ISCO: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, AXIM Biotechnologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AXIM Biotechnologies Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where AXIM Biotechnologies's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2025) EBITDA data.
AXIM Biotechnologies (AXIM) has a Debt-to-EBITDA of 3.86 as of Jun. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on AXIM Biotechnologies. According to the industry distribution chart, AXIM Biotechnologies ranks #274 out of 291 companies in the Biotechnology industry, placing it in the top 94.2%.
Is AXIM Biotechnologies' Debt-to-EBITDA too high?
AXIM Biotechnologies' current Debt-to-EBITDA is 3.86. The Biotechnology industry median Debt-to-EBITDA is 1.16. AXIM Biotechnologies' value of 3.86 is 232.8% above this industry median. Based on the distribution chart, AXIM Biotechnologies ranks #274 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does AXIM Biotechnologies' Debt-to-EBITDA compare to ZVSA and HEPA?
According to the Biotechnology industry distribution chart, AXIM Biotechnologies ranks #274 out of 291 companies for Debt-to-EBITDA. This places AXIM Biotechnologies in the lower half of its industry. The industry median Debt-to-EBITDA is 1.16. AXIM Biotechnologies' value of 3.86 is 232.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.16, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AXIM Biotechnologies's current Debt-to-EBITDA of 3.86 is 232.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on AXIM Biotechnologies. For the Biotechnology industry, the median Debt-to-EBITDA is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AXIM Biotechnologies's current Debt-to-EBITDA is 3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Debt-to-EBITDA of 3.86. The current Debt-to-EBITDA is 3.86 and 232.8% above the Biotechnology industry median of 1.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Debt-to-EBITDA is 3.86 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AXIM has been successfully added to your 